Premium
Renal Effects of SGLT‐2 Inhibitors and Other Anti‐diabetic Drugs: Clinical Relevance and Potential Risks
Author(s) -
Lioudaki E,
Whyte M,
Androulakis ES,
Stylianou KG,
Daphnis EK,
Ganotakis ES
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.731
Subject(s) - medicine , renal function , diabetes mellitus , type 2 diabetes mellitus , canagliflozin , kidney disease , disease , type 2 diabetes , population , pharmacology , empagliflozin , intensive care medicine , endocrinology , environmental health
Type 2 diabetes mellitus (T2DM) is a metabolic disease affecting an increasing percentage of general population worldwide. Patients with T2DM are frequently characterized by impaired renal function, primarily as a result of diabetic kidney injury, but also by other contributing factors, such as hypertension, atherosclerosis, and medications. Sodium‐glucose cotransporter (SGLT)‐2 inhibitors have emerged as a new, promising class of antidiabetic agents with actions that seem to extend beyond their hypoglycemic effect.